Endometriosis is an oestrogen-dependent, chronic inflammatory disease that affects 10% of reproductive-aged women. Current treatment options depend on female sex steroid hormone modulation; however, all have side effects and are not useful in women who want to conceive. microRNAs treatments have provided promising results for some chronic diseases and cancers. We have previously shown the microRNA Let-7b is repressed in endometriosis and that loss of Let-7 contributes to
| INTRODUCTION
Endometriosis has many symptoms that negatively affect both the reproductive capability and professional/social life of affected women. 1 This disease is characterized by the proliferation and growth of endometrial tissue outside of the uterine cavity that causes pelvic pain and infertility. 2, 3 The incidence of the endometriosis is approximately 10% in reproductive-aged women and 20%-50% of women with infertility or pelvic pain. 4 The pathophysiology of endometriosis is not well understood; therefore, current treatment options for endometriosis are limited to manipulation of female sex steroid hormones. 5, 6 These treatment options have significant side effects and are all contraindicated in women wishing to conceive.
Nonhormonal therapies that specifically target the endometriosis are in a sequence-specific fashion, blocking translation or leading to mRNA degradation. 7 miRNAs have a major role in regulation of development and in cellular homeostasis. 8, 9 Additionally, aberrant microRNA expression is linked to many diseases such as cancer, 10 cardiovascular disorders 11 and inflammatory diseases. 12 microRNAs are the potent regulators of gene expression in endometriosis. 13 Distinct miRNA expression profiles have been identified in microarray studies of eutopic and ectopic endometrial tissue samples. 13 We previously reported that circulating microRNAs, including Let-7b-5p, were significantly decreased in the serum of disease. 14, 15 Further, we have reported decreased Let-7 family members in endometriosis tissue where they are involved in the regulation of genes such as KRAS and aromatase. 16, 17 These studies prompted us to hypothesize that miRNA Let-7b-5p might have a major role in the pathogenesis and treatment of endometriosis.
Here, we report the therapeutic use of miRNA Let-7b-5p in the treatment of endometriosis in a murine model.
| MATERIALS AND METHODS

| Animals
Six-to eight-week-old C57BL/6J wild-type female mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mice were maintained in the animal facility of Yale School of Medicine.
They housed five animals per cage in a 12-hour light, 12-hour dark cycle (7 AM-7 PM) with ad libitum access to food and water. 
| Induction of endometriosis in mice
Endometriosis was induced in ten mice using a modified version of the syngeneic endometriosis protocol that has been used previously in our laboratory. 18 In accordance with this model, identical sizes of uterine tissue fragments were sutured onto the peritoneal surface. Three mice in oestrus stage were killed using a CO 2 chamber, both uterine horns from each mouse were removed and opened longitudinally and divided into equal fragments measuring 4 mm 2 . These fragments were preserved on ice in DMEM/F12 Table 1 . The specificity of the amplified transcript and absence of primer dimers were confirmed by a melting curve analysis. Gene expression was normalized to that of β-actin as an internal control. Relative mRNA expression was calculated using the comparative cycle threshold (Ct) method (2 −ΔCT ). 19, 20 All experiments were carried out three times and each in duplicate.
| 5347
| Immunohistochemistry analysis
Lesions were fixed in 4% paraformaldehyde and embedded in paraffin.
Five-micrometre tissue sections were mounted on slides followed by 
| Statistical analysis
GraphPad Prism 7.0 a software (GraphPad Software, La Jolla, CA, USA) was used for all statistical analyses. All in vitro experiments were performed in triplicate, and the mean for each individual animal was used for statistical analysis. The quantitative data were tested for normality using the Shapiro-Wilk test. Non-normally distributed continuous variables were compared using Mann-Whitney U test.
Student t test was used for evaluating of normally distributed variables. P < 0.05 was considered as statistically significant. Let-7b-treated and control mice. We also specifically measured the area of endometrial tissue and determined that it was also significantly reduced in Let-7b-treated mice compared to control mice, as shown in Figure 1E .
| RESULTS
| Let-7b treatment and evaluation of lesions
| Differential expression of genes that are involved in endometriosis
The effect of Let-7b treatment on expression of genes that are involved in endometriosis was determined by qRT-PCR in the lesions and compared with expression in the control group. We observed decreased expression of several genes known to mediate endometriosis growth or endometriosis-associated inflammation.
Expression of ER-α, ER-β, Cyp19a, KRAS 4A, KRAS 4B and IL-6 was all decreased in the Let-7b treatment group compared to control group. The quantitative decrease in gene expression is 11.7-fold (P = 0.02) for ER-α, 3.3-fold (P = 0.02) for ER-β, 8.9-fold (P = 0.02) for Cyp19a, 22.6-fold (P = 0.02) for IL-6, 10.9-fold (P = 0.02) for KRAS 4A and 4.6-fold (P = 0.04) for KRAS 4B in Let-7b-treated group compared to untreated group as shown in Figure 2A . Expression levels of the IGF-1, cyclin-D1, MMP-2, TLR-4 and IL-10 were unchanged between the two groups (P > 0.05) as shown in Figure 2B . 
T A B L E 1 Primer sequences used for gene expression by qRT-PCR
Gene
Forward sequence Reverse sequence
ER-α TCTGCCAAGGAGACTCGCTACTGT GCTTGGCCAAAGGTTGGCAG
ER-ß GCCAACCTCCTGATGCTTCTTT TTGTACCCTCGAAGCGTGTGA
CYP19A1
CTTGGCTGTAGGGGGCATAC GCGCTATTTGGCCTGAGTTG
KRAS4A
AGATGTGCCTATGGTCCTGGTAG CAATCTGTACTGTCGGATCTCTCTC
KRAS4B
GATGTGCCTATGGTCCTGGTAG CATCGTCAACACCCTGTCTTG
IL-6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC
IGF-1 GGTGGTTTATGAATGGTT AGGGTGTGTCTAATGGAG
Cyclin-D1 AAGTGCGTGCAGAAGGAGATTGT GGATAGAGTTGTCAGTGTAGATGC
MMP-2 CCCTCAAGAAGATGCAGAAGTTC TCTTGGCTTCCGCATGGT
TLR-4 TTCAGAACTTCAGTGGCTGGATT CCATGCCTTGTCTTCAATTGTTT
IL-10
| DISCUSSION
We identify a novel, nonhormonal therapy for endometriosis that is based on differential expression of a miRNA in endometriosis. The treatment of endometriosis by intraperitoneal injections of miRNA Let-7b in a murine model appears very promising given that the altered expression of this miRNA is also a key driver of human endometriosis. 21 Delivery of miRNA Let-7b intraperitoneally in mice showed decreased lesion growth and decreased levels of genes that have a role in the pathophysiology of endometriosis. These results support our hypothesis that miRNAs, especially Let-7b, may be useful as a therapeutic agent/s for the treatment of endometriosis.
Macroscopic evaluation of lesions is one of the tests for determining effectiveness of endometriosis treatment. Therefore, lesions were initially compared using total volume. However, most of the lesions were compromised of fluid-filled cystic structures in this rodent endometriosis model. Histologic tissue evaluation proved a more accurate technique than measuring lesion size. Therefore, we speculate that the fluid containing portions of the cystic lesions would also resolve over time as the endometriosis-mediated fluid production and inflammation dissipate.
Let-7b has tumour suppressor activity and regulates cell cycle. 10 Suppression of Let-7 family members has been reported in many cancers. [21] [22] [23] KRAS, a potent proto-oncogene, 24 ,25 is mutated in a wide variety of human malignancies [26] [27] [28] [29] [30] [31] and up-regulated in endometriosis. Activation of mutated KRAS in transplanted endometrium triggers endometriosis in mice. 32 Similarly, we have shown that a polymorphism of a Let-7-binding site in KRAS 3′-UTR causes abnormal KRAS expression as well as increased proliferation and invasion in endometriosis. 16 Let-7b regulates KRAS expression by binding to one or more of 10 Let-7 complementary sites (LCS) in the 3′-UTR of the KRAS gene. 33 Here, we show that both the KRAS 4A
and 4B isoforms as well as total KRAS protein expression levels were diminished in the Let-7b treatment group.
Endometriosis is an oestrogen-dependent disease, and oestrogen receptors ER-α and β have a role in endometriosis. 34 Breast cancer is another oestrogen-dependent disease where Let-7 also represses oestrogen signalling. 37 Further, down-regulation of Let-7 miRNAs has been reported in breast tumour-initiating cells (BT-IC), and restoration of Let-7 in these cells caused reduced proliferation and mammosphere formation in vitro as well as tumour formation and metastasis in NOD/SCID mice. 38 We, previously identified stem cells in endometrium and endometriosis. [39] [40] [41] It will be interesting to see whether Let-7 also regulates stem cells in endometriosis in a similar manner to regulation of BT-IC in breast cancers. In our model, ER-α expression was more strongly suppressed than ER-β with Let-7b miRNA suggesting that Let-7 blocks oestrogen stimulation in the treatment of endometriosis. These data suggest a targeted means of blocking sex steroid action in endometriosis without the systemic side effects of whole-body oestrogen deprivation.
Aromatase P450 has an essential role in oestrogen synthesis and has been demonstrated to regulate local oestrogen production in endometriosis. 42 Shibahara et al 43 showed that high Let-7f expression was significantly correlated with low aromatase protein levels in primary breast cancer stromal cells. They also identified a Let-7f binding site in Cyp19a1, indicating that the aromatase gene is a direct target of Let-7f. 43 We demonstrated similar results in endometrial stromal cells from endometriosis patients and in Ishikawa cells. 17 In our study, significantly increased Let7b and Let-7f expression levels were determined after aromatase inhibitor treatment. Further, decreased aromatase expression and reduced endometrial cell migration were shown after Let-7f mimic transfection. 17 High levels of Let-7b after aromatase inhibitor treatment indicated that Let-7b has a role in aromatase regulation and decreased aromatase levels after Let-7b treatment supported that Let-7b treatment reduces local oestrogen production and action.
Endometriosis is also a chronic inflammatory disease, and macrophages have a principal role in this inflammatory process. An increase in M1 type macrophages is seen in endometriosis. 44 Let-7b may regulate inflammation through its known target gene TLR-4, which regulates M1 macrophage response. 45 We observed a trend towards decreased levels of TLR-4 in the Let-7b treatment group compared to controls. Another inflammatory marker, IL-6, levels were significantly suppressed in the Let-7b treatment group. These results suggest that Let-7b treatment does reduce inflammation associated with endometriosis.
In this study, a local treatment route was used for miRNA treatment. The effective delivery of the oligonucleotides to target cells after systemic administration is not very effective as they are eliminated from the bloodstream by hepatic degradation. Therefore, many of the systemic oligonucleotide treatment studies have focused on liver disease. 46 Various types of oligonucleotide carriers have been used to resolve these problems; however, none of them has fully accomplished targeted oligonucleotide delivery. 47 The most effective oligonucleotide-based drugs approved by the U.S. Food where local delivery is very effective. 48 We suggest that this drug would work best as an intraperitoneal therapy delivered at the time of surgery or by injection. Further, dose response and safety studies will be required prior to human application.
In conclusion, microRNA Let-7b treatment of endometriosis resulted in decreased oestrogen signalling (ER and Cyp19A1), decreased KRAS and decreased inflammatory signalling (IL-6). The pleiotropic effects of Let-7b treatment suggest that multiple complementary mechanisms were responsible for the actions of Let-7b in endometriosis. These numerous effects suggest the potential for a more comprehensive endometriosis therapy without the systemic effects, a common feature of current drugs.
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